985 related articles for article (PubMed ID: 25529339)
1. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.
Wilson JG; Liu KD; Zhuo H; Caballero L; McMillan M; Fang X; Cosgrove K; Vojnik R; Calfee CS; Lee JW; Rogers AJ; Levitt J; Wiener-Kronish J; Bajwa EK; Leavitt A; McKenna D; Thompson BT; Matthay MA
Lancet Respir Med; 2015 Jan; 3(1):24-32. PubMed ID: 25529339
[TBL] [Abstract][Full Text] [Related]
2. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Matthay MA; Calfee CS; Zhuo H; Thompson BT; Wilson JG; Levitt JE; Rogers AJ; Gotts JE; Wiener-Kronish JP; Bajwa EK; Donahoe MP; McVerry BJ; Ortiz LA; Exline M; Christman JW; Abbott J; Delucchi KL; Caballero L; McMillan M; McKenna DH; Liu KD
Lancet Respir Med; 2019 Feb; 7(2):154-162. PubMed ID: 30455077
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
4. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: a randomized, controlled trial.
Villar J; Kacmarek RM; Pérez-Méndez L; Aguirre-Jaime A
Crit Care Med; 2006 May; 34(5):1311-8. PubMed ID: 16557151
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.
Bellingan G; Maksimow M; Howell DC; Stotz M; Beale R; Beatty M; Walsh T; Binning A; Davidson A; Kuper M; Shah S; Cooper J; Waris M; Yegutkin GG; Jalkanen J; Salmi M; Piippo I; Jalkanen M; Montgomery H; Jalkanen S
Lancet Respir Med; 2014 Feb; 2(2):98-107. PubMed ID: 24503265
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.
Zheng G; Huang L; Tong H; Shu Q; Hu Y; Ge M; Deng K; Zhang L; Zou B; Cheng B; Xu J
Respir Res; 2014 Apr; 15(1):39. PubMed ID: 24708472
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
[TBL] [Abstract][Full Text] [Related]
8. Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study.
Farge D; Loisel S; Resche-Rigon M; Lansiaux P; Colmegna I; Langlais D; Charles C; Pugnet G; Maria ATJ; Chatelus E; Martin T; Hachulla E; Kheav VD; Lambert NC; Wang H; Michonneau D; Martinaud C; Sensebé L; Cras A; Tarte K
Lancet Rheumatol; 2022 Feb; 4(2):e91-e104. PubMed ID: 38288741
[TBL] [Abstract][Full Text] [Related]
9. A clinical classification of the acute respiratory distress syndrome for predicting outcome and guiding medical therapy*.
Villar J; Fernández RL; Ambrós A; Parra L; Blanco J; Domínguez-Berrot AM; Gutiérrez JM; Blanch L; Añón JM; Martín C; Prieto F; Collado J; Pérez-Méndez L; Kacmarek RM;
Crit Care Med; 2015 Feb; 43(2):346-53. PubMed ID: 25393701
[TBL] [Abstract][Full Text] [Related]
10. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.
Skrahin A; Ahmed RK; Ferrara G; Rane L; Poiret T; Isaikina Y; Skrahina A; Zumla A; Maeurer MJ
Lancet Respir Med; 2014 Feb; 2(2):108-22. PubMed ID: 24503266
[TBL] [Abstract][Full Text] [Related]
11. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome.
Needham CJ; Brindley PG
Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome.
Simonson OE; Mougiakakos D; Heldring N; Bassi G; Johansson HJ; Dalén M; Jitschin R; Rodin S; Corbascio M; El Andaloussi S; Wiklander OP; Nordin JZ; Skog J; Romain C; Koestler T; Hellgren-Johansson L; Schiller P; Joachimsson PO; Hägglund H; Mattsson M; Lehtiö J; Faridani OR; Sandberg R; Korsgren O; Krampera M; Weiss DJ; Grinnemo KH; Le Blanc K
Stem Cells Transl Med; 2015 Oct; 4(10):1199-213. PubMed ID: 26285659
[TBL] [Abstract][Full Text] [Related]
13. Effects of sustained inflation and postinflation positive end-expiratory pressure in acute respiratory distress syndrome: focusing on pulmonary and extrapulmonary forms.
Tugrul S; Akinci O; Ozcan PE; Ince S; Esen F; Telci L; Akpir K; Cakar N
Crit Care Med; 2003 Mar; 31(3):738-44. PubMed ID: 12626977
[TBL] [Abstract][Full Text] [Related]
14. An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome.
Villar J; Pérez-Méndez L; López J; Belda J; Blanco J; Saralegui I; Suárez-Sipmann F; López J; Lubillo S; Kacmarek RM;
Am J Respir Crit Care Med; 2007 Oct; 176(8):795-804. PubMed ID: 17585106
[TBL] [Abstract][Full Text] [Related]
15. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
16. Stem cell therapy for acute respiratory distress syndrome: a promising future?
Horie S; Masterson C; Devaney J; Laffey JG
Curr Opin Crit Care; 2016 Feb; 22(1):14-20. PubMed ID: 26645555
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial.
Villar J; Belda J; Añón JM; Blanco J; Pérez-Méndez L; Ferrando C; Martínez D; Soler JA; Ambrós A; Muñoz T; Rivas R; Corpas R; Díaz-Dominguez FJ; Soro M; García-Bello MA; Fernández RL; Kacmarek RM;
Trials; 2016 Jul; 17():342. PubMed ID: 27449641
[TBL] [Abstract][Full Text] [Related]
18. Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial.
McIntyre LA; Stewart DJ; Mei SHJ; Courtman D; Watpool I; Granton J; Marshall J; Dos Santos C; Walley KR; Winston BW; Schlosser K; Fergusson DA; ;
Am J Respir Crit Care Med; 2018 Feb; 197(3):337-347. PubMed ID: 28960096
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell therapy for COVID-19 acute respiratory distress syndrome: a double-blind randomised controlled trial.
Martínez-Muñoz ME; Payares-Herrera C; Lipperheide I; Malo de Molina R; Salcedo I; Alonso R; Martín-Donaire T; Sánchez R; Zafra R; García-Berciano M; Trisán-Alonso A; Pérez-Torres M; Ramos-Martínez A; Ussetti P; Rubio JJ; Avendaño-Solà C; Duarte RF
Bone Marrow Transplant; 2024 Jun; 59(6):777-784. PubMed ID: 38409332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
